| Literature DB >> 23599759 |
Huanran Liu1, Zhen Zhang, Takafumi Tabuchi, Shouyu Wang, Jiangning Wang.
Abstract
Cytokines exhibit a pleiotropic effect in the regulation of the immune cell function, tumor growth and antitumor immune responses. A total of 30 patients with colorectal carcinoma were enrolled on this study and their levels of interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α, serum granulocyte colony-stimulating factor (sG-CSF) and serum macrophage colony-stimulating factor (sM-CSF) were measured preoperatively using ELISA. Tumor-infiltrating granulocyte (TIG), tumor-associated macrophage (TAM), G-CSF and M-CSF expression in tumor cells were examined using immunostaining. This study revealed abnormal levels of cytokines in patients, including IL-1β (1/30, 3.3%), IL-6 (16/30 53.3%), IL-81 (15/30, 50%), TNF-α (4/21, 19%), sG-CSF (17/30, 56.7%) and sM-CSF (4/21, 19%). There was a positive linear correlation between IL-6 and sM-CSF (P=0.017, R=0.517). sG-CSF was significantly associated with a deeper tumor invasion (P=0.039) and a more advanced tumor stage (P=0.023). The granulocyte/lymphocyte (G/L) ratio was associated with abnormal levels of sG-CSF. Logistic univariate analysis revealed that TIGs were a risk factor for lymph node metastasis (0.019) and TAMs were a risk factor for depth of invasion (0.029), but this was not confirmed in logistic multivariate analysis. In conclusion, IL-6, IL-8, sM-CSF and sG-CSF may indirectly promote tumor growth, progression and metastasis by changing the leukocyte populations in the blood and the tumor microenvironment.Entities:
Keywords: colorectal carcinoma; cytokine; granulocyte colony-stimulating factor; granulocyte/lymphocyte ratio; interleukin-6; macrophage-colony stimulating factor
Year: 2013 PMID: 23599759 PMCID: PMC3628903 DOI: 10.3892/ol.2013.1176
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1Immunohistochemical assay for TAMs, TIGs, tM-CSF and tG-CSF. TAMs, tumor-associated macrophages; TIGs, tumor-infiltrating granulocytes; tM-CSF, macrophage colony-stimulating factor expression in tumor cells; tG-CSF, granulocyte colony-stimulating factor expression in tumor cells.
Correlation between cytokines and G/L ratio.
| Variable | IL-6 | sM-CSF | sG-CSF | IL-8 | IL-1β | TNF-α | G/L ratio | TIGs |
|---|---|---|---|---|---|---|---|---|
| sM-CSF | ||||||||
| R | 0.517 | |||||||
| P-value | 0.017 | |||||||
| sG-CSF | ||||||||
| R | 0.369 | |||||||
| P-value | 0.045 | 0.56 | ||||||
| IL-8 | ||||||||
| R | ||||||||
| P-value | 0.63 | 0.75 | 0.37 | |||||
| IL-1β | ||||||||
| R | ||||||||
| P-value | 0.90 | 0.99 | 0.56 | 0.43 | ||||
| TNF-α | ||||||||
| R | ||||||||
| P-value | 0.44 | 0.69 | 0.44 | 0.89 | 0.62 | |||
| G/L ratio | ||||||||
| R | ||||||||
| P-value | 0.24 | 0.89 | 0.45 | 0.58 | 0.65 | 0.67 | ||
| TIGs | ||||||||
| R | 0.43 | |||||||
| P-value | 0.945 | 0.320 | 0.364 | 0.445 | 0.297 | 0.050 | 0.888 | |
| TAMs | ||||||||
| R | 0.32 | |||||||
| P-value | 0.64 | 0.75 | 0.33 | 0.09 | 0.67 | 0.49 | 0.40 | 0.579 |
Spearman's test;
Pearson's test. There was a significant correlation between IL-6 and sM-CSF (P=0.017) and between TAMs and TIGs (P=0.024). IL, interleukin; sM-CSF, serum macrophage colony-stimulating factor; sG-CSF, serum granulocyte colony-stimulating factor; TNF-α, tumor necrosis factor-α; G/L ratio, granulocyte/lymphocyte ratio; TIGs, tumor-infiltrating granulocytes; TAMs, tumor-associated macrophages.
Figure 2Correlation between the tumor stage and G/L ratio. G/L, granulocyte/lymphocyte.
Figure 3Effects of cytokine levels. Kruskal-Wallis testing revealed that sG-CSF was significantly increased in the abnormal IL-6 level group (P= 0.022); the G/L ratio was associated with abnormal levels of sG-CSF (P=0.049); IL-8 was significantly decreased in the high sG-CSF level group (P= 0.026); TAMs were associated with abnormal levels of IL-8 (P= 0.037). sG-CSF, serum granulocyte colony-stimulating factor; G/L, granulocyte/lymphocyte; IL, interleukin, TAMs, tumor-associated macrophages.
Association of cytokines with clinicopathological factors.
| Variable | Cytokines according to tumor features (pg/ml) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Lymph node metastasis | Depth of invasion | Tumor stage | |||||||
|
|
|
| |||||||
| Absent | Present | P-value | Under muscle layer | Beyond muscle layer | P-value | Stage 0 and I | Stage II, III and IV | P-value | |
| sG-CSF | 26.5±7.6 | 32.2±11.2 | NS | 23.9±4.1 | 31.4±11.1 | 0.039 | 22.7±4.1 | 32.4±10.7 | 0.023 |
| sM-CSF | 504±241.4 | 359.2±172.5 | NS | 407.3±208.82 | 399±138.9 | NS | 470.7±295.1 | 389.0±188.9 | NS |
| IL-1β | 0.32±0.2 | 0.28±0.2 | NS | 0.4±0.3 | 0.2±0.1 | 0.086 | 0.35±0.2 | 0.28±0.2 | NS |
| IL-6 | 23.3±62.5 | 5.0±7.1 | NS | 2.4±1.4 | 12.9±17.2 | NS | 2.52±2.1 | 12.48±38.4 | NS |
| IL-8 | 10.9±4.2 | 16.1±14.4 | NS | 9.9±2.0 | 16.0±8.9 | NS | 10.2±2.5 | 15.6±13.6 | NS |
| TNF-α | 1.0±0.6 | 1.3±0.4 | NS | 1.0±0.3 | 1.2±0.6 | NS | 1.0±0.5 | 1.2±0.8 | NS |
| TIGs | 33.9±12.5 | 53.1±22.9 | 0.065 | 40.3±16.5 | 49.5±23.1 | NS | 40.6±18.2 | 50.2±21.9 | NS |
| TAMs | 32.4±16.8 | 32.5±28.3 | NS | 42.6±22.5 | 29.4±25.5 | NS | 46.2±39.0 | 26.6±20.4 | NS |
Results are presented as mean ± SD.
Includes muscle layer. sG-CSF was significantly associated with deeper tumor invasion (P=0.039) and more advanced tumor stage (P=0.023, Rs=0.375).sG-CSF, serum granulocyte colony-stimulating factor; sM-CSF, serum macrophage colony-stimulating factor; IL, interleukin; TNF-α, tumor necrosis factor-α; TIGs, tumor-infiltrating granulocytes; TAMs, tumor-associated macrophages; NS, not significant.
Figure 4Correlation between CSF expression in tumor cells and the level of serum CSF. There was no significant correlation between tM-CSF and the level of sM-CSF (P=0.442) and between tG-CSF and the level of sG-CSF (P= 0.498). CSF, colony-stimulating factor; tM-CSF, macrophage CSF expression in tumor cells; sM-CSF, serum macrophage CSF; tG-CSF, granulocyte CSF expression in tumor cells; sG-CSF, serum granulocyte CSF.
Logistic regression analysis of risk factors for lymph node metastasis and depth of invasion.
| Multivariate
| |||
|---|---|---|---|
| Variable | Univariate P-value | P-value | RR (95% CI) |
| Lymph node metastasis | |||
| G-CSF | 0.269 | ||
| M-CSF | 0.124 | ||
| IL-1β | 0.731 | ||
| IL-6 | 0.15 | ||
| IL-8 | 0.703 | ||
| TNF-α | 0.452 | ||
| TIGs | 0.019 | 0.069 | 1.087 (0.994–1.188) |
| TAMs | 0.353 | ||
| sG-CSF | 0.517 | ||
| sM-CSF | 0.676 | ||
| Depth of invasion | |||
| G-CSF | 0.083 | 0.071 | 1.301 (0.978–1.733) |
| M-CSF | 0.939 | ||
| IL-1β | 0.083 | ||
| IL-6 | 0.517 | ||
| IL-8 | 0.567 | ||
| TNF-α | 0.59 | ||
| TIGs | 0.262 | ||
| TAMs | 0.029 | 0.063 | 0.64 (0.927–1.002) |
| sG-CSF | 0.619 | ||
| sM-CSF | 0.422 | ||
-2 Log likelihood = 17.811, Nagel kerke R2 = 0.422;
-2 Log likelihood = 9.362, Nagel kerke R2 = 0.659. CI, confidence interval; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; IL, interleukin; TNF-α, tumor necrosis factor-α; TIGs, tumor-infiltrating granulocytes; TAMs, tumor-associated macrophages; sG-CSF, serum G-CSF; sM-CSF, serum M-CSF.